Genomic Vision: Postponement of the ordinary general meeting of shareholders of June 28, 2022

BAGNEUX, France, June 27, 2022–(BUSINESSWIRE)–Regulatory News:

Genomic Vision (FR0011799907 – GV, PEA-PME eligible – the “Company”) (Paris:GV)a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications, informs its shareholders that, in view of the requests for admission cards, postal voting forms and proxies received at today by the Company, the ordinary general meeting of shareholders initially scheduled for June 28, 2022 cannot be held, for lack of the quorum required to deliberate validly.

The management board has therefore taken the decision to postpone said general meeting and to convene a new ordinary general meeting of shareholders called to rule, on second call, on the same agenda as the general meeting of June 28, 2022, on Monday July 11. 2022 at 2 p.m. at the Company’s registered office.

The notice of second meeting will be published in the BALO (Bulletin des Annonces Légales Obligatoires) on June 29, 2022 and will contain the terms of participation and voting at said meeting.

In accordance with the provisions of Articles R. 225-77 and R. 225-79 of the French Commercial Code, the postal voting forms sent to the Company and the mandates given for the general meeting initially scheduled for June 28, 2022 remain valid from then on. that the book entry of the securities is maintained.

We remind you that the shareholders were informed of the agenda and the text of the resolutions of the general meeting, initially scheduled for June 28, 2022, in the notice of meeting published in BALO n°61 of May 23, 2022 which remain unchanged.

***

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company that develops products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in the technologies of editing of the genome and in bioproduction processes. GENOMIC VISION’s proprietary tools based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed for reliable characterization of DNA alterations in the genome. These tools are notably used to monitor DNA replication in cancer cells, for the early detection of cancers and for the diagnosis of genetic diseases. Based in Bagneux, in the Paris region, GENOMIC VISION is listed on the regulated Euronext market in Paris, Compartment C (Euronext: GV – ISIN: FR0011799907).

www.genomicvision.com

Index Member CAC® Mid & Small and CAC® All-Tradable

WARNING

This press release contains implicitly or expressly forward-looking statements relating to Genomic Vision and its activities. Genomic Vision believes that these forward-looking statements are based on reasonable assumptions. However, no guarantee can be given as to the achievement of the forecasts expressed in these forward-looking statements which are subject to risks, including those described in the “Risk Factors” section of the Universal Registration Document filed with the Autorité des Marchés Financiers (AMF) on April 14, 2022 and which is available on the company’s website (www.genomicvision.com) and changes in economic conditions, financial markets and markets in which Genomic Vision is present. The forward-looking statements contained in this press release are also subject to risks unknown to Genomic Vision or that Genomic Vision does not consider material at this date. The realization of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Genomic Vision to differ materially from the results, financial conditions, performances or achievements expressed in these forward-looking statements.

This press release and the information it contains do not constitute, nor shall they be interpreted as an offer or invitation to sell or subscribe, or the solicitation of any order or invitation to buy or subscribe to Genomic Vision shares. in any country. The distribution of this press release in certain countries may constitute a violation of the legal provisions in force. Persons in possession of the press release must therefore inform themselves of any local restrictions and comply with them.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20220627005614/en/

contacts

Genomic Vision
Dominique Remy-Renou
President of the Management Board
Such. : +33 1 49 08 07 51
investors@genomicvision.com

Ulysses Communication
Press relations
Bruno Arabian
Such. : +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor Relations
& Strategic Communications
Such. : +33 1 44 71 94 94
gv@newcap.eu

We would like to thank the author of this write-up for this outstanding content

Genomic Vision: Postponement of the ordinary general meeting of shareholders of June 28, 2022


Take a look at our social media accounts and also other pages related to themhttps://www.ai-magazine.com/related-pages/